The Microplastics Panic

How the environmental–litigation complex hijacks unsettled science

A wave of high-profile research over the past several years has taken microplastics from a story about pollution in oceans, drinking water, and food to a far more alarming claim: that these particles are “inside you”—in brains, blood, arteries, placentas and testes—and may be tied to serious disease, including cancer and cardiovascular harm. There have been thousands of stories echoing this narrative in the media and on advocacy networks, often framed as proof of corporate malfeasance. A slew of lawsuits is already in the works.

But, in a recent twist, those assumptions are in dispute. A growing swath of scientists says the most widely reported detections may be false positives that reflect contamination and methodological limitations, not proof of widespread internal plastic accumulation, and certainly not proof of harm.

Rather than facing a growing health crisis as so many previous headlines had argued, many experts say the studies claiming to find cancer-causing particles rely on measurement systems that are not robust enough to distinguish genuine plastic signals from ubiquitous lab background or from tissue that can mimic common polymers.

The scare narrative began to fracture publicly in January with an article in The Guardian, a notable venue because it had helped to popularize the “microplastics are inside your body” storyline. The investigation reported that many analytical chemists and other scientists believe the widespread claims and alarmist academic papers are wrong or overstated. Vox republished it, and Fast Company, The Conversation, and The Washington Post followed up with their own analytical pieces. The New York Times, which had featured a range of credulous stories, videos, and even school guides on microplastics’ health threats, ignored the new evidence entirely, and in fact has ran a story reiterating the now-challenged conclusions this week.

The Guardian called its investigation a “bombshell”, and it was, but not just for the medical community. If the critics are right, the revelations cut directly at the rhetorical heart of what has verged on a panic: the leap from “we can detect something plastic-like” to “microplastics are driving disease,” the “settled medical verdict” that had acted as narrative accelerant. But it never was.

The turnaround has reverberated through the ecosystem that helped manufacture the former consensus—a familiar “panic pipeline” that has repeatedly elevated other contested health scares in recent years made up of overlapping networks of environmental advocacy groups, plaintiffs’ lawyers, activist academics, and a media ecosystem that reliably rewards the most alarming interpretations first.

Microplastic Fears Go Mainstream

How did we get to the point where a tentative conclusion was widely reported as definitive? Concern over microplastics has been building for roughly two decades. For much of that time, it focused on floating trash, degraded bottles, and the unsettling idea that plastic doesn’t disappear so much as it fractures into tiny specks that show up on beaches, and in seafood and drinking water. In reviews of the early evidence, the European Food Safety Authority in 2016 and the World Health Organization in 2019 underscored just how tentative the claims about direct health effects were—in part because most ingested particles were expected to pass through the gut with limited absorption. They urged better methods and more rigorous research, but the advocacy groups and the media rarely restrained their reporting.

The narrative escalated dramatically in March 2024 when a New England Journal of Medicine (NEJM) study reported the presence of plastic particles in carotid artery plaque and an association with heart attack, stroke, and death. In an interview with The Guardian, the paper’s lead author, Italian scientist and physician Raffaele Marfella, coined the slogan: “plastic-free is healthy for the heart and the Earth,” claiming “we are defenseless against plastic pollution.”

The findings were uniquely combustible. “Microplastics in the body” media stories can feel abstract; “NEJM study links plastics in arteries to death” does not. The study went viral, widely reported as a “smoking gun.” The Guardian used especially loaded language, characterizing human blood vessels as “contaminated” and describing the findings as “potentially life-threatening.”

What was once speculative science quickly hardened into a popular belief that microplastics are an immediate and escalating health threat. The framing moved from “plastics are everywhere” to “plastics can kill you”—often in ways that read as evidence of a settled causal mechanism for heart attack and stroke.

Concerns heightened even more in February 2025 after an analysis published in Nature Medicine claimed to find trace plastics in the brain. The Guardian, once again, was all in with a shocking headline: “Levels of microplastics in human brains may be rapidly rising.” The study claimed there was a rising trend in micro- and nanoplastics found in tissue from dozens of postmortems carried out between 1997 and 2024.

Narrative Reversal

Alarmism sells, and many outlets treated early microplastics “detections” as verdicts, not hypotheses. But many experts in the field were never convinced of the gravity of the claims. Last year, nine measurement specialists pushed back in a letter in Nature Medicine, arguing that the February 2025 brain study had too few contamination safeguards and too little validation, making its reported levels hard to trust.

“This paper is really bad—and it is very explainable why it is wrong,” said co-author Dr Dušan Materić, an analytical chemist at the Helmholtz Centre for Environmental Research in Germany. And it isn’t just about brains: placenta, lipid-rich tissues, and atherosclerotic plaque are exactly the kinds of samples where normal biology can mimic plastic signals.

The fight shifted from “plastic pollution exists” to whether headline “plastic in human tissue” findings are robust enough to support disease claims. A major target of the skepticism is Py-GC-MS, a heat-based test that some researchers say can misread tissue chemistry as polyethylene or PVC in complex samples.

But even perfect detection wouldn’t settle the bigger point: “found” isn’t the same as “harmful,” and “harmful” isn’t the same as “high risk at real-world concentrations.” Risk assessment requires a chain of evidence, not a single detection: hazard is not the same as risk, association is not causation, and detection is not validated identification.

The Scare Narrative Ecosystem

Confusion between hazard and risk is a recurring feature of chemical scares. The plastics controversy follows a familiar U.S. “panic pipeline” where advocacy groups, activist academics and plaintiffs’ firms turn contested hazard signals into class action suits. We’ve seen that arc with products and chemicals regarded by regulators and mainstream scientific bodies as generally safe: talc, glyphosate, BPA, antidepressants, Gardasil, and now Tylenol.

Environmental groups moved quickly to frame microplastics as an established health threat. The most vocal, Environmental Working Group, has acknowledged support from plaintiff lawyers (here, here, here). It has published twenty microplastics stories in the past three years, half through its New Lede project edited by Carey Gillam, who has also written microplastics pieces for The Guardian.

Gillam is a polarizing figure in these debates: A former Reuters reporter who left the news agency in 2015 after widespread criticism of her reporting on GMOs and crop chemicals, her work on GMOs and crop chemicals has leaned toward advocacy framing. Her books, Whitewash: The Story of a Weedkiller, Cancer, and the Corruption of Science and The Monsanto Papers, became treasure troves for litigators. Wisner Baum (formerly Baum Hedlund) and its associated counsel, Robert F. Kennedy, Jr., coordinated with Gillam in preparing the first successful glyphosate lawsuit—and features in a “Monsanto Papers” section on its website.

In her various articles on plastics and the threats of the chemical industry, Gillam’s go-to academic scientists are Stanford University professor Tracey Woodruff and pediatrician and Boston College epidemiologist Philip Landrigan. They both run programs with missions and messaging that align well with litigation-laden crises and are often quoted together in articles as experts on chemicals. They co-authored with other scientists the launch article for The Lancet Countdown on Health and Plastics, which characterized plastics as a “grave, growing, and under-recognized danger to human and planetary health, and got huge play in the media.

Woodruff was a prominent voice in the endocrine-disruptor/plastic chemicals campaigns aimed at banning the plasticizer BPA (bisphenol A), a chemical found in microscopic quantities in some plastic products and on store receipts, as a reproductive toxin. But the crisis narrative ran into headwinds. The Obama administration funded $30 million in research into its safety and found no basis to ban or restrict it. Nevertheless, the campaign became the centerpiece of environmental groups for years and a target of thousands of lawsuits. Ironically, BPA has been displaced in plastics by BPS even though it is considered even more toxic—a reminder of the “regrettable substitution” dynamic that often follows chemical scares.

Microplastics are Woodruff’s current focus. For 18 years until February she was director of UCSF’s Program on Reproductive Health, which, according to its mission statement, targets “harmful chemicals.” It also houses what it calls “The Poison Papers—documents from encounters with Monsanto and the EPA. Its Center to End Corporate Harm describes plastics and petrochemicals as “health-harming industries” engaged in a “decades-long assault” on regulators—language that reads less like neutral research and more like a prosecution brief. It features a link—“Serve as an expert witness”—and highlights Woodruff by name. Its Risk Management has a section that reads, “A law firm wants to hire me as their expert witness,” and notes it is the individual’s choice whether to serve.

Landrigan is not just a mainstream pediatric epidemiologist; he’s also a high-profile environmental-health advocate whose chemical-risk messaging has drawn pushback from other scientists. He was senior author two years ago of the American Academy of Pediatrics’ GMO guidance that singled out glyphosate residues as a threat to child-health. Science magazine and numerous scientists called it “fearmongering.”

In a letter to The Guardian, Landrigan was dismissive of its investigation that challenged claims that microplastics may not pose a health threat after all. “Microplastics harm health,” he wrote, calling them “Trojan horses” that carry plastic additives into the body and cause diseases “from cancer to heart disease and from IQ loss in children to decreased fertility.”

Landrigan also chairs the Science Advisory Board of the Heartland Health Research Alliance (HHRA)—a nonprofit formed by environmental groups to manage and fund the “Heartland Study”—a vehicle used by tort law firms to feed litigation narratives targeting corporations that make chemical products. Heartland was launched with seed money from Robert F. Kennedy, Jr. and a principal at Wisner Baum, which has used their research in numerous lawsuits.

Its director, Charles Benbrook, is an economist and organic industry consultant with a long history of controversy. He was an organic industry funded adjunct professor at Washington State University before being fired in 2016 for failing to disclose industry-funded conflicts of interest. Benbrook has served as an expert witness in more than a dozen lawsuits involving GMOs and pesticides, and since 2014 he has been a paid consultant for mass tort pesticide litigators on class action cases involving glyphosate, paraquat and chlorpyrifos, often with Baum Hedlund. He has acknowledged receiving more than $500,000 in related consulting associated with pesticide lawsuits. Landrigan and Benbrook have also co-authored articles on the dangers of chemicals.

HHRA’s vice-chair is Robin Greenwald of Weitz & Luxenberg, whose experience includes environmental and consumer class-action cases. Greenwald was appointed co-lead counsel in the federal Roundup (glyphosate) MDL, a role that sits at the center of mass-tort coordination. With Landrigan holding a leadership role at HHRA, critics point out the tight link between the production of alarming health claims, policy campaigns, and legally actionable narratives.

How the Microplastics Narrative Became Lawsuit-Ready

The conflict over whether the direction of environmental-health research is being distorted by advocacy and links to the plaintiffs’ bar is not unique to microplastics. But microplastics are uniquely suited to the feedback loop because the story is so emotionally powerful (“harmful plastic inside you”), analytically difficult (easy to overinterpret), and legally portable (products, exposure, alleged concealment). The early litigation template has already formed in high-profile litigation alleging consumer-fraud even while measurement standards and proof of causality are still uncertain.

That combination helps to explain why concerns about microplastics were able to shift so quickly from uncertainty about chemical detection methods to courtroom-ready claims about injury and culpability—and why the January 2026 methodological backlash lands as a challenge not only to a few journal articles, but also to the narrative supply chain that turned them into the source of justified public alarm.

It is not just the influence of academia and “public interest” NGOs at work, of course. The plaintiffs’ ecosystem itself is now openly building “microplastics dockets”: Law firms and websites that generate “leads” for potential litigants are advertising investigations, soliciting clients, and packaging unsettled science into allegations of “negligence,” “toxicity,” “exposure,” and “injury.” Bloomberg Law has described microplastics as a target in a “surge” of lawsuits and noted that repeat-player firms are behind multiple filings in the space. One of many examples: The Lyon Firm publicly states it is “reviewing new cases” involving “microplastics” in food products and invites readers to contact its attorneys for a “free consultation.”

If the scientific debate seems academic, the legal system has been weighing whether it is actionable. Over the last two years, consumer class action lawsuits have increasingly been built on a single, fear-amplifying, litigation-tempting premise: Products marketed as “pure,” “safe,” or “natural” are, it is alleged, contaminated with harmful microplastics and, therefore, are deceptively marketed.

A March 2024 complaint against BlueTriton’s Poland Spring water, for instance, alleged that “every bottle … contains dangerous levels of microplastics.” In May 2025, a federal court dismissed with prejudice a putative class action lawsuit which alleged that Fiji Water’s “Natural Artesian Water” labeling was deceptive due to purported microplastic contamination. The court faulted, among other issues, the inadequacy of the plaintiff’s testing allegations. Meanwhile, the microplastics theory has migrated far beyond bottled water to Ziploc bags, Rubbermaid food containers, and baby bottles.

What is striking and relevant to litigation is how “concentrated” some of this docket is: Multiple microplastics class action lawsuits across different consumer categories are often filed by the same plaintiffs’ firms, notably Clarkson Law, Todd M. Freeman, and Ahdoot and Woolfson, in what seems a coordinated effort to build a scalable “microplastics” theory of liability.

This is where the measurement controversy becomes legally explosive. If courts require product-specific proof—and if the foundational “microplastics are found in human tissue” literature is itself challenged as actually being contamination and misidentification—the evidentiary scaffolding beneath many plaintiffs’ pleadings becomes harder to build. That pressure is already visible in bottled-water rulings emphasizing plausibility and testing specificity.

Allegations of harm, even absent proof, can greatly skew public opinion and the results of litigation. Once a threat narrative has become culturally established, it becomes monetizable. That extends to more than tort litigation. It also includes a growing ecosystem of “microplastics detox” claims and boutique, snake-oil interventions marketed to anxious consumers—all despite continued uncertainty about internal dose, persistence, and demonstrated harm caused by typical degrees of exposures.

What We Know—and What We Don’t

None of the scientific pushback argues that plastic pollution is imaginary. The Guardian’s investigation stresses that plastic pollution in the natural world is ubiquitous and that people are exposed via food, drink and air. What the backlash challenges is the over-stated confidence about the causality between internal accumulation and harm.

In other words, the public conversation has sprinted to “we’re contaminated and sick,” while the scientific community is still uncertain about whether existing technology can reliably distinguish plastic from the natural tissues in which it is supposedly embedded. That’s why the current rhetoric seems, at the very least, premature.

There is a rational environmental agenda around plastics—waste reduction, smarter materials, and less unnecessary packaging. But turning tentative, contamination-prone detection into a confident claim of a “silent epidemic” risks misdirecting policy, rewarding perverse research incentives, and eroding trust in future research findings.

There is a larger, structural point as well: The near-hysteria over microplastics in the human body is emerging as a case study in how modern “chemical panics” are manufactured and amplified—not only by activists and sympathetic media, but also by a litigation economy that profits when anxiety hardens into presumption. Once a claim becomes culturally “true” (“it’s in your organs,” “it’s causing disease,” and “industry covered it up”), it becomes legally actionable: a ready-made grievance, a monetizable exposure story, a recruitment pitch, and a lure to mass filings. Considering the unqualified headlines that have long accompanied reporting on this issue, pressure to settle unjustified claims is almost a given.

That same fear-to-filing pipeline has appeared repeatedly in other chemical and technology controversies. This is especially true in cases where the science is genuinely complex, the evidence is contested, and the public is primed for a villain. We’ve seen versions of it in litigation and advocacy storms involving talc, herbicides, food additives, vaccines, and other products—where thin or unsettled evidence is treated as final, where “presence” is sold as “harm,” and where the courtroom becomes a substitute arena for scientific closure.

The danger is not that microplastics concerns will be studied too rigorously; rather, it is that misaligned incentives will keep selecting for the most alarming interpretation of uncertain findings: Alarm is what recruits plaintiffs, drives donations, generates headlines, and sustains an expert-witness and litigation-promoting marketplace.

If the backlash against the “plastics-are-killing-us” narrative proves anything, it is that once a “hidden killer” storyline takes hold—solidified in the public consciousness and often embedded in policy—backtracking requires a chain of unlikely reversals: Regulators must walk back prior claims, agencies need to revise already-issued regulations, and newsrooms must replace a scare storyline with the messier conditional reality. That kind of coordinated de-escalation is rare.

Even as scientists attempt to correct the misinformation around plastics, we should not expect a rollback from the loudest constituencies who have benefited substantially from the alarm: Advocacy groups will continue mobilizing around the politicized narrative, which plaintiff law firms will leverage for recruitment. Microplastics-related litigation is already beginning to scale—especially municipal nuisance suits and consumer-fraud class actions. Even as the science on microplastics improves and data accumulate, expect repeat bellwether “test” trials, expert battles, and settlement leverage. In this ecosystem, alarm is rewarded immediately; sound science has a lonely audience and an indolent path.

Jon Entine is the executive director of the Science Literacy Project/Genetic Literacy Project.

Henry I. Miller is a physician and molecular biologist and the Glenn Swogger Distinguished Scholar at the Science Literacy Project. He was the co-discoverer of the RNA-dependent RNA polymerase in the influenza virus and the founding director of the U.S. Food and Drug Administration’s Office of Biotechnology.